We are currently enrolling patients with Waldenstrom’s macroglobulinemia (WM) in a CLOVER-WaM pivotal study utilizing iopofosine. Iopofosine is also being evaluated in a multi cohort CLOVER-1 Phase 2 study in adult B-cell malignancies and the CLOVER-2 Phase 1 study for a variety of pediatric cancers.
Additionally, we are currently collaborating with BBK Worldwide to provide new concierge services for patients participating in some of Cellectar's current clinical studies. To learn more about how both Cellectar and BBK Worldwide are working to improve the patient experience, click here.
Clinical Studies Are Key To Finding New and Better Treatments
Clinical studies are a fundamental necessity in the development and advancement of new treatment options for battling cancer, and you may not know it, but you could play an important role. Clinical studies need patients to enroll in them so that they can advance through the processes necessary to potentially get a new treatment to market. Your participation in clinical studies may help create a better treatment landscape for future cancer patients.
To learn more general information about clinical studies, please visit www.cancer.org and find the "Clinical Studies" section.